Semaglutide (Ozempic) Initiation and Management Guidelines

Dosing and Titration

Initial titration: Begin with 0.25 mg subcutaneously once weekly for 4 weeks in adults with type 2 diabetes to reduce early gastrointestinal adverse events such as nausea and vomiting. [Mayo Clinic] 1
Maintenance dose: After the 4‑week titration, increase to 0.5 mg subcutaneously once weekly for ongoing glycemic control. [Mayo Clinic] 2
Further escalation: If additional glucose lowering is required, the dose may be increased to 1.0 mg once weekly after at least 4 weeks on the 0.5 mg dose. [Mayo Clinic] 1
Administration timing: The injection can be given on any day of the week, with or without meals. [Mayo Clinic] 2
Rationale for gradual escalation: A stepwise increase in dose markedly lowers the incidence of gastrointestinal side effects compared with rapid dose escalation. [American Gastroenterological Association] 3 ; [American Diabetes Association] 4

No renal dose adjustment: Semaglutide does not require dosage modification for any stage of renal impairment, including end‑stage renal disease. [Mayo Clinic] 1

Absolute contraindications:
- Personal or family history of medullary thyroid carcinoma. [American College of Cardiology] 5
- Presence of multiple endocrine neoplasia type 2 (MEN 2). [American College of Cardiology] 5
- Prior serious hypersensitivity reaction to semaglutide. [American College of Cardiology] 5
Cautions (use with clinical judgment):
- History of pancreatitis – discontinue semaglutide if pancreatitis is suspected. [American College of Cardiology] 5
- Existing diabetic retinopathy – monitor closely in high‑risk patients (diabetes duration ≥10 years). [American Diabetes Association] 4
- Risk factors for gallbladder disease – assess risk before initiating therapy. [American Gastroenterological Association] 3 ; [American Diabetes Association] 4

Holding before surgery: For elective procedures, discontinue semaglutide at least 7 days prior to the operation to mitigate delayed gastric emptying and reduce aspiration risk. [Society of Anesthesiologists] 6

Approximately 40 % of patients receiving semaglutide experience nausea and about 16 % develop diarrhea; these gastrointestinal events are most common during the initial dose‑escalation phase. 7

Hyperthyroidism due to active, untreated Graves disease should be brought to euthyroid status before starting semaglutide, because uncontrolled thyroid hormone excess can exacerbate weight‑loss‑related metabolic disturbances. 8, 9

First‑line therapy for Graves hyperthyroidism consists of thiamazole (methimazole) or carbimazole, initiated at 0.4–0.8 mg per kilogram of body weight per day, not exceeding a total daily dose of 30 mg. 10, 8
Propylthiouracil is contraindicated for Graves disease except during the first trimester of pregnancy, owing to its risk of hepatotoxicity. 8
The typical duration of antithyroid drug therapy is 12–18 months to achieve remission in most patients. 8, 9
Thyroid function monitoring during antithyroid treatment should be performed monthly (TSH and free T4) until a euthyroid state is reached, then every 2–3 months thereafter. 9

When a thyroidectomy is planned as definitive treatment for Graves disease, semaglutide should be discontinued at least 7 days before surgery to reduce the risk of aspiration from delayed gastric emptying. 8
Patients must be confirmed euthyroid before any surgical intervention to minimize peri‑operative cardiovascular complications. 8

Graves disease is an autoimmune condition driven by stimulating TSH‑receptor antibodies, leading to hyperthyroidism; this mechanism is distinct from the C‑cell origin of medullary thyroid carcinoma, the specific tumor type associated with the semaglutide boxed warning. 11, 10